Envelope 2 protein phosphorylation sites S75 & 277 of hepatitis C virus genotype 1a and interferon resistance: A sequence alignment approach

详细信息    查看全文

• 作者：Samia Afzal (1)
  Muhammad Idrees (1)
  Muhammad Ali (1)
  Muhammad Ilyas (1)
  Abrar Hussain (1)
  Madiha Akram (1)
  Sadia Butt (1)
  Sana Saleem (1)
  Irshad ur Rehman (1)
  Liaqat Ali (1)
  Muhammad Shahid (1)
  
• 刊名：Virology Journal
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：8
• 期：1
• 全文大小：520KB
• 参考文献：1. Khan S, Rai MA, Khan A, Farooqui A, Kazmi SU, Ali SH: Prevalence of HCV and HIV infections in 2005-Earthquake-affected areas of Pakistan. / BMC Infect Dis 2008, 8:147. CrossRef
  2. Alter MJ: Epidemiology of hepatitis C virus infection. / World J Gastroenterol 2007, 13:2436鈥?441.
  3. Brown RS: Hepatitis C and liver transplantation. / Nature 2005, 436:973鈥?78. CrossRef
  4. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. / Lancet Infect Dis 2005, 5:558鈥?67. CrossRef
  5. Idrees M, Lal A, Naseem M, Khalid M: High prevalence of hepatitis C virus infection in the largest province of Pakistan. / J Dig Dis 2008, 9:95鈥?03. CrossRef
  6. Bartenschlager R, Lohmann V: Replication of hepatitis C virus. / J Gen Virol 2000, 81:1631鈥?648.
  7. Jhaveri R, Kundu P, Shapiro AM, Venkatesan A, Dasgupta A: Effect of Heptitis C Virus Core Protein on Cellular Gene Expression: Specific Inhibition of Cyclooxygenase 2. / The Journal of Infectious Diseases 2005, 191:1498鈥?06. CrossRef
  8. Brass V, Moradpour D, Blum HE: Molecular virology of hepatitis C virus (HCV): 2006 update. / Int J Med Sci 2006, 3:29鈥?4.
  9. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. / Hepatology 2004, 39:5鈥?9. CrossRef
  10. Budkowska A: Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction. / Pol J Microbiol 2009, 58:93鈥?8.
  11. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C. / Hepatology 2002, 36:S121鈥?27. CrossRef
  12. Keam SJ, Cvetkovic RS: Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. / Drugs 2008, 68:1273鈥?317. CrossRef
  13. Grandvaux N, tenOever BR, Servant MJ, Hiscott J: The interferon antiviral response: from viral invasion to evasion. / Curr Opin Infect Dis 2002, 15:259鈥?67. CrossRef
  14. Katze MG, He Y, Gale M: Viruses and interferon: a fight for supremacy. / Nat Rev Immunol 2002, 2:675鈥?87. CrossRef
  15. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R: Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. / J Gen Virol 2001, 82:723鈥?33.
  16. Lauer GM, Walker BD: Hepatitis C virus infection. / N Engl J Med 2001, 345:41鈥?2. CrossRef
  17. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. / Gastroenterology 2006, 131:1887鈥?898. CrossRef
  18. Hayashi J, Stoyanova R, Seeger C: The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. / Virology 2005, 335:264鈥?75. CrossRef
  19. Cocquerel L, Kuo CC, Dubuisson J, Levy S: CD81-dependent binding of hepatitis C virus E1E2 heterodimers. / J Virol 2003, 77:10677鈥?0683. CrossRef
  20. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM: Analysis of a successful immune response against hepatitis C virus. / Immunity 1999, 10:439鈥?49. CrossRef
  21. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T: Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. / J Virol 2008, 82:7034鈥?046. CrossRef
  22. Kaufman RJ: The Double-stranded RNA-activated Protein Kinase PKR. In / Translational Control of Gene Expression. / Volume 39. 2nd edition. Cold Spring Harbor Laboratory Press; 2000:503鈥?27.
  23. Pe'ery T, Mathews MB: Viral translational strategies and host defense mechanisms. In / Translational Control of Gene Expression. / Volume 39. 2nd edition. Cold Spring Harbor Laboratory Press; 2000:371鈥?24.
  24. Gale M Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. / Virology 1997, 230:217鈥?27. CrossRef
  25. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. / Science 1999, 285:107鈥?10. CrossRef
  26. MacQuillan GC, Caterina P, de Boer B, Allan JE, Platten MA, Reed WD, Jeffrey GP: Ultra-structural localisation of hepatocellular PKR protein using immuno-gold labelling in chronic hepatitis C virus disease. / J Mol Histol 2009, 40:171鈥?76. CrossRef
  27. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. / Annu Rev Biochem 1998, 67:227鈥?64. CrossRef
  28. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG: Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. / Mol Cell Biol 1998, 18:5208鈥?218.
  29. Blom N, Gammeltoft S, Brunak S: Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. / J Mol Biol 1999, 294:1351鈥?362. CrossRef
  30. Obenauer JC, Cantley LC, Yaffe MB: Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. / Nucleic Acids Res 2003, 31:3635鈥?641. CrossRef
  31. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: UCSF Chimera--a visualization system for exploratory research and analysis. / J Comput Chem 2004, 25:1605鈥?612. CrossRef
  32. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. / Electrophoresis 1997, 18:2714鈥?723. CrossRef
  33. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. / Nucleic Acids Res 1994, 22:4673鈥?680. CrossRef
  34. Felsenstein J: Evolutionary trees from DNA sequences: a maximum likelihood approach. / J Mol Evol 1981, 17:368鈥?76. CrossRef
  35. Zhang Y: I-TASSER server for protein 3D structure prediction. / BMC Bioinformatics 2008, 9:40. CrossRef
  36. Gaudy C, Lambele M, Moreau A, Veillon P, Lunel F, Goudeau A: Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. / J Clin Microbiol 2005, 43:750鈥?54. CrossRef
  37. Trepo C LK, Niederau C, / et al.: Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C. / J Hepatol 2000, 32:29. CrossRef
  38. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, / et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. / N Engl J Med 2000, 343:1666鈥?672. CrossRef
  39. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Takahashi N, / et al.: Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. / Hepatology 2000, 32:1138鈥?144. CrossRef
  40. Guo JT, Bichko VV, Seeger C: Effect of alpha interferon on the hepatitis C virus replicon. / J Virol 2001, 75:8516鈥?523. CrossRef
  41. Mathews MB, Hershey JWB, Sonenberg N: / Translational Control. NY.: Cold Spring Harbor Laboratory Press, Cold Spring Harbor; 1996.
  
• 作者单位：Samia Afzal (1)
  Muhammad Idrees (1)
  Muhammad Ali (1)
  Muhammad Ilyas (1)
  Abrar Hussain (1)
  Madiha Akram (1)
  Sadia Butt (1)
  Sana Saleem (1)
  Irshad ur Rehman (1)
  Liaqat Ali (1)
  Muhammad Shahid (1)
  
  1. National Centre of Excellence in Molecular Biology, 87-West Canal Bank Road, Thokar Niaz Baig, Lahore-53700, University of the Punjab, Lahore, Pakistan
  
• ISSN：1743-422X

文摘

Background Hepatitis C is a major health problem affecting more than 200 million individuals in world including Pakistan. Current treatment regimen consisting of interferon alpha and ribavirin does not always succeed to eliminate virus completely from the patient's body. Results Interferon induced antiviral protein kinase R (PKR) has a role in the hepatitis C virus (HCV) treatment as dsRNA activated PKR has the capacity to phosphorylate the serine and threonine of E2 protein and dimerization viral RNA. E2 gene of hepatitis C virus (HCV) genotype 1 has an active role in IFN resistance. E2 protein inhibits and terminates the kinase activity of PKR by blocking it in protein synthesis and cell growth. This brings forward a possible relation of E2 and PKR through a mechanism via which HCV evades the antiviral effect of IFN. Conclusion A hybrid in-silico and wet laboratory approach of motif prediction, evolutionary and structural anlysis has pointed out serine 75 and 277 of the HCV E2 gene as a promising candidate for the serine phosphorylation. It is proposed that serine phosphorylation of HCV E2 gene has a significant role in interferon resistance.